{"schema_version":"1.0","type":"article","title":"Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門","url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html","markdown_url":"https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.md","lang":"zh-Hant","date":"2026-07-30","publish_at":"2026-07-30T08:00:00+08:00","updated_at":"2026-07-30","category":"製藥巨頭系列","topic":"製藥巨頭系列","tags":["Astellas","Xtandi","Padcev","Vyloy","腫瘤","藥物開發"],"summary":"Xtandi 仍主導安斯泰來腫瘤收入；Padcev、Vyloy 與下一代 CLDN18.2 資產能否在 LOE 後形成可重複的產品平台，才是下一段考題。","key_points":[],"facts":[],"sections":["第一層：四款產品已成形，但營收重心仍高度集中","第二層：產品銷售不等於安斯泰來可以完整留下的經濟利益","第三層：Padcev 已跨進治癒意圖場景，下一關是臨床採納","第四層：Vyloy 先拿到門票，但 CLDN18.2 不會永遠只有一位玩家","第五層：Xospata 提供底座，卻不能被誤寫成更廣泛的 AML 平台","第六層：公司已為 Xtandi 之後準備資本，但目標不是成果","四道驗證門：什麼時候才可以說平台真的成立？","結論：安斯泰來已不是「只有 Xtandi」，但還不能提前封王","一級來源"],"references":[],"images":[{"alt":"安斯泰來不再只有 Xtandi，但產品組合仍高度集中","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform/01_%E4%B8%8D%E6%98%AF%E5%8F%AA%E6%9C%89Xtandi_%E4%BB%8D%E9%AB%98%E5%BA%A6%E9%9B%86%E4%B8%AD.png"},{"alt":"Padcev 從晚期治療走進膀胱癌手術前後","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform/02_Padcev%E8%B5%B0%E9%80%B2%E6%89%8B%E8%A1%93%E5%89%8D%E5%BE%8C.png"},{"alt":"安斯泰來已形成跨癌種、跨模態的平台雛形","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform/03_%E5%B9%B3%E5%8F%B0%E9%9B%9B%E5%BD%A2_%E5%9B%9B%E5%B8%82%E5%A0%B4%E4%B8%89%E6%A8%A1%E6%85%8B.png"},{"alt":"評估安斯泰來腫瘤平台的四道驗證門","url":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform/04_%E5%9B%9B%E9%81%93%E9%A9%97%E8%AD%89%E9%96%80.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/astellas-oncology-platform/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-07-30）。Xtandi 之後，安斯泰來靠誰？從單一明星藥到腫瘤平台的四道驗證門。https://drugnews.com.tw/articles/2026-07-23-astellas-oncology-platform.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-07-23-astellas-oncology-platform-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}